AUSTIN, Texas--(BUSINESS WIRE)--The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that John Barr has been appointed to Apollo’s Board of Directors as an independent director, effective immediately. Mr. Barr will join 9 other directors, a majority of whom are independent under the rules and regulations of the United States Securities and Exchange Commission, and will serve as a member of the Audit and Nominating and Governance Committees.
“John is a highly accomplished leader in the medical device field and an experienced board member who brings a wealth of executive leadership skills and experience to our board,” said Rich Meelia, Chairman of Apollo’s Board of Directors. “We are confident that he will add great value to our Board of Directors and that Apollo will benefit from his insights, judgment and counsel.”
Mr. Barr began his current role as an operating partner with Altamont Capital Partners in January of 2018. He previously served as CEO and a member of the Board of Surgical Specialties Corporation from 2014 through 2017 and, prior to that, held a number of CEO and Executive leadership positions during a career spanning more than 35 years, in healthcare. Mr. Barr holds a masters degree in finance, accounting, and economics from the J.L. Kellogg Graduate School of Management-Northwestern University, and an undergraduate degree in bioengineering from the University of Pennsylvania.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal defect repairs to the interventional treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 70 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo’s common stock is traded on Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.
© 2019 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: the advancement and development of Apollo’s existing products and technologies; reports of adverse events related to our products or related procedures; reimbursement decisions by private or government payors; physician adoption and recommendations of procedures utilizing our products and other factors detailed in Apollo’s periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2018. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
